• A sample drawn by the previous supplier of a Hep C study conducted for a large pharmaceutical company in the US was made up of only 14% non-Caucasians. According to the CDC, non-Caucasians made up 35% of the Hep C cases of chronic HCV in the US in 2000Thus, the previous supplier’s study was drawn from an incorrect sample.
    ​  
  • Both of our subsequent studies were composed of a representative sample that included the correct proportions.

Hep C Study Shows Why ​Sampling Matters 

Our respondents mirrored actual US patient universe

THE ONLY PROVIDER OF SCIENTIFICALLY VALID PATIENT CHART AUDIT / TREATING PHYSICIAN RESEARCH

© 2014-2017 Clarity Pharma Research LLC  |  All Rights Reserved​ Privacy Policy
To learn more about our services, call (864) 208-0078 or contact information@claritypharma.com.
Subscribe to our newsletter at: http://eepurl.com/ovQcb